AltPep, Backed by Section32 and Lilly, Gets $53M to Catch and Treat Early Alzheimer’s

“What if you could screen everyone at age 40, with a simple blood test, that could detect trace amounts of the toxic forms of amyloid-beta protein that build up over 10-20 years in people with Alzheimer’s? What if the blood test had 99 percent sensitivity and specificity to the toxic forms of the protein structure, ignoring normal forms? What if you could go a step further after a positive early diagnosis, and give a treatment that binds the same way, but is optimized to clear out those misfolded proteins before they start bunching up into plaques that damage neurons to the point of no return?”

The Risk of AIRA

Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).

Valerie Daggett, PhD

Chief Executive Officer

Valerie, the CEO/Founder of AltPep and an Endowed Professor of Bioengineering at the University of Washington, has been a champion of groundbreaking research for over 30 years. Her inherent curiosity pushes her to uncover new ways of tackling problems in the field of amyloid diseases, where successes are few.  Her tenacity led to a revolutionary discovery of a protein structure that could dramatically change the diagnosis and treatment of Alzheimer’s disease and over 50 other amyloid diseases. At AltPep, Valerie leads a team of innovators who are developing this platform to make the early, pre-symptomatic diagnosis and treatment of amyloid diseases a reality. Valerie holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.